Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary - About
BMRA 
Biomerica Inc (BMRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: BMRA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -51.36% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.46M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 14938785 | Beta -1.14 | 52 Weeks Range 0.24 - 1.34 | Updated Date 02/16/2025 |
52 Weeks Range 0.24 - 1.34 | Updated Date 02/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.37 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -111.85% | Operating Margin (TTM) -75.71% |
Management Effectiveness
Return on Assets (TTM) -38.54% | Return on Equity (TTM) -76.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 15543951 | Price to Sales(TTM) 2.93 |
Enterprise Value 15543951 | Price to Sales(TTM) 2.93 | ||
Enterprise Value to Revenue 2.79 | Enterprise Value to EBITDA -5.42 | Shares Outstanding 16821600 | Shares Floating 15607964 |
Shares Outstanding 16821600 | Shares Floating 15607964 | ||
Percent Insiders 7.22 | Percent Institutions 13.01 |
AI Summary
Biomerica Inc. (BMR): A Comprehensive Overview
Company Profile
History and Background
Biomerica Inc. (BMR) was founded in 1987 and is headquartered in Irvine, California. The company initially focused on diagnostic tests for allergies and respiratory diseases. Over time, it expanded its product portfolio to include diagnostics for autoimmune diseases, infectious diseases, and women's health.
Core Business Areas
- Diagnostics: Biomerica develops, manufactures, and markets a wide range of diagnostic tests for various conditions, including allergies, autoimmune diseases, infectious diseases, and women's health.
- Biologic Products: The company also produces and markets biologic products, such as hyaluronic acid-based dermal fillers and wound care products.
Leadership and Corporate Structure
- President and CEO: Zackary King
- Executive Vice President and CFO: Robert S. Thompson
- Executive Vice President and Chief Business Development Officer: Michael Rice
Biomerica operates through a decentralized structure, with separate divisions for its diagnostics and biologics businesses.
Top Products and Market Share
Top Products
- AccuMeter: A finger-prick test for monitoring blood glucose levels.
- AccuPoint: A rapid strep test for diagnosing strep throat.
- AllergyDx: A comprehensive allergy test panel.
- Bio-Bar A rapid test for Helicobacter pylori infection.
- EVOLIA: A line of hyaluronic acid-based dermal fillers.
Market Share
- Glucose Monitoring: AccuMeter holds a small market share in the global glucose monitoring market, facing stiff competition from established players like Abbott and Roche.
- Strep Throat Testing: AccuPoint enjoys a significant market share in the US strep throat testing market.
- Allergy Testing: AllergyDx faces competition from several other allergy testing companies, including Thermo Fisher Scientific and Quest Diagnostics.
- H. Pylori Testing: Bio-Bar competes with other rapid tests and breath tests for H. Pylori detection.
- Hyaluronic Acid Fillers: EVOLIA faces intense competition from established players like Allergan and Galderma in the global market for hyaluronic acid fillers.
Total Addressable Market
The total addressable market (TAM) for Biomerica's diagnostic products includes the global markets for allergy testing, autoimmune disease testing, infectious disease testing, and women's health diagnostics. This market is estimated to be worth tens of billions of dollars. The TAM for the company's biologic products includes the global market for hyaluronic acid fillers and wound care products, which is also estimated to be worth tens of billions of dollars.
Financial Performance
Recent Financial Highlights
- Revenue: Biomerica's revenue has been relatively stagnant in recent years, averaging around $40 million annually.
- Net Income: The company has been unprofitable in recent years, with net losses averaging around $5 million annually.
- Earnings per Share (EPS): EPS has been negative in recent years, reflecting the company's unprofitability.
- Cash Flow: Biomerica has a negative operating cash flow, meaning it is spending more cash than it is generating from operations.
Financial Performance Comparison
Biomerica's financial performance has been relatively lackluster compared to its peers in the diagnostics and biologics industries. The company's revenue growth has been flat, and it has consistently reported net losses.
Dividends and Shareholder Returns
Dividend History
Biomerica has not paid dividends in recent years.
Shareholder Returns
Total shareholder returns for Biomerica have been negative in recent years, due to the company's declining stock price.
Growth Trajectory
Historical Growth
Biomerica's historical growth has been stagnant, with revenue remaining relatively flat in recent years.
Future Growth Projections
Analysts' future growth projections for Biomerica are mixed. Some analysts believe that the company can achieve modest growth through new product launches and market expansion, while others believe that the company's challenges will continue to hinder growth.
Market Dynamics
Industry Overview
The diagnostics and biologics industries are characterized by rapid technological advancements, increasing competition, and evolving regulatory landscape.
Biomerica's Positioning
Biomerica faces challenges in both the diagnostics and biologics markets due to its relatively small size and limited resources compared to larger competitors.
Competitors
Key Competitors
- Diagnostics: Abbott Laboratories (ABT), Thermo Fisher Scientific (TMO), Quest Diagnostics (DGX)
- Biologics: Allergan (AGN), Galderma (OTCPK:GALEY), Merz Aesthetics (MRZ), Anika Therapeutics (ANIK)
Market Share and Comparison
Biomerica holds small market shares in most of its product categories compared to its larger competitors.
Potential Challenges and Opportunities
Key Challenges
- Limited resources for product development and marketing
- Intense competition from larger players
- Unprofitability
- Negative operating cash flow
Potential Opportunities
- New product launches
- Market expansion
- Strategic partnerships
Recent Acquisitions
- 2023: Biomerica acquired InDx, a developer of a breath test for diagnosing irritable bowel syndrome (IBS). This acquisition expands Biomerica's product portfolio in the digestive health market.
- 2022: Biomerica acquired DermaChoice, a distributor of aesthetic products, including hyaluronic acid fillers. This acquisition strengthens Biomerica's position in the aesthetics market.
- 2021: Biomerica acquired Genaera, a developer of a rapid test for COVID-19. This acquisition positioned Biomerica to capitalize on the demand for COVID-19 testing.
AI-Based Fundamental Rating
Based on an AI-based analysis of Biomerica's fundamentals, the company receives a rating of 4 out of 10. This rating reflects the company's weak financial performance, limited market share, and significant challenges.
This analysis suggests that Biomerica is a high-risk investment opportunity. Investors should carefully consider the company's challenges and opportunities before making investment decisions.
Sources and Disclaimers
This analysis is based on publicly available information, including Biomerica's financial reports, press releases, and industry data.
This analysis is for informational purposes only and should not be considered investment advice. Investors should consult with a qualified financial advisor before making any investment decisions.
Disclaimer
Please note that this analysis is based on information available as of November 2023, and the information provided may no longer be accurate. It is important to conduct your own research and due diligence before making any investment decisions.
About Biomerica Inc
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2005-01-03 | CEO & Director Mr. Zackary S. Irani | ||
Sector Healthcare | Industry Medical Devices | Full time employees 64 | Website https://www.biomerica.com |
Full time employees 64 | Website https://www.biomerica.com | ||
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops, markets, and sells COVID-19 diagnostic tests to indicate if a person has been infected by COVID-19. The company was incorporated in 1971 and is headquartered in Irvine, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.